In order to understand the contribution of hypoxia to tumour progression, resistance to treatment, and, in the future, to exploit differential expression of hypoxia-related factors in tumours vs normal tissue for therapeutic gain, we have examined the expression of CA IX in breast cancer and related this to clinico-pathological parameters and clinical outcome. The gene discussed is CA9; the disease is neoplasm.